The Longevity Blogs editorial team covers health. Articles are researched and drafted with the help of AI tools, and each one lists the sources it draws on so every claim can be checked.
39 articles
The Muscle Paradox: GLP-1 Therapy, Lean Mass Loss, and Emerging Skeletal Risks While GLP-1 receptor agonists such as semaglutide and tirzepatide remain dominant...
Why 2026 is a turning point for getting geroscience therapies to older adults As of May 12, 2026, developers of therapies aimed at aging biology face a regulato...
Why the induction method matters Life Biosciences’ ER‑100, the first partial‑reprogramming therapy to receive an FDA IND, uses a doxycycline‑inducible system to...
Summary In early 2026 Life Biosciences received FDA clearance of an IND for ER‑100, opening a Phase 1, first‑in‑human, single‑dose safety trial in open‑angle gl...
Why different geroscience tools demand different trials The partial epigenetic reprogramming approach represented by ER‑100 (AAV2‑delivered OSK) and two classes...
A focused look at why ER-100’s clinical protocol looks the way it does Life Biosciences’ ER-100 program—cleared by the FDA to begin a Phase 1 study in early 202...
What happened and why it matters now Life Biosciences announced U.S. Food and Drug Administration (FDA) clearance of an investigational new drug (IND) applicati...
Why 2026 feels like a turning point for longevity clinics Growth in private longevity clinics, expanded telemedicine prescribing flexibilities, and a simultaneo...
Why the idea of a “staged” evidence pathway matters now Over the past 18 months regulators and sponsors have produced a set of operational precedents that, take...
Regulatory momentum: two complementary shifts In the first four months of 2026 the FDA published a draft guidance that explicitly endorses practical use of Baye...
Summary In the last 12–18 months U.S. geroscience has moved from isolated pilot projects toward a coordinated translational stack: new center grants and cores,...
Where the human data stand Over the past two years a small but growing set of randomized and pilot human trials has begun to test whether rapamycin or related "...